Cyclacel lead drug likely to fail trial, says safety board

(Reuters) – Cyclacel Pharmaceuticals Inc said an independent committee had determined that its lead drug was unlikely to show a statistically significant improvement in the survival rates in some leukemia patients. The company’s stock plunged nearly 69 percent to 89 cents in premarket trading on Tuesday. Cyclacel’s oral drug, sapacitabine, is being tested in a late-stage study in patients with acute myeloid leukemia, who are unfit for or have refused intensive chemotherapy. …
Go to Source